TNGX logo

TNGX Tango Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$21.73
-0.98 (-4.32%)

Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase …

Market Cap: $3.68Bwww.tangotx.com

Price

No data yet.

Social Signal Score

54
5d
—
30d
57
4 mentions
—
60d
53
9 mentions
—
90d
53
10 mentions
—
news: 10

Analyst Ratings

14 analysts
Buyconsensus
Strong Buy 0Buy 13Hold 1Sell 0Strong Sell 0
Avg price target$50.5+132.4%
Low $35Median $46.5High $69
Current Consensus

Revenue

$0.00-100.00%
$-11.26M$10.43M$32.12M$53.81M
Mar 2020Sep 2026

Analyst Estimates

FY2025
$-0.87
$-0.90–$-0.83
8 analysts
FY2026
$-1.51
$-1.57–$-1.49
10 analysts
FY2027
$-1.85
$-2.41–$-1.42
11 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Malte Peters
Sector
Healthcare
Industry
Biotechnology
Employees
137
Beta
1.22
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
40.87
www.tangotx.com